Esophago-gastric (EG) cancer represents one of the cancers with the fastest rising incidence globally with 5-year overall survival of 15.1%. The variability of early signs in EG cancer result in only one-third of patients being suitable for potentially curative treatment at diagnosis. Chemotherapy +/- radiotherapy may have a role in this pathway however radical surgical resection remains critical to achieving long-term disease-free survival for our patients. Surgical techniques for junctional Esophago-Gastric adenocarcinoma vary with particular controversy and much scientific discussion regarding the optimal approach for Siewert Type II Esophago-Gastric cancers. The advent of minimally invasive techniques including thoracoscopic, laparoscopic and robotic have enhanced the EG resectional options and also bring significant potential short-term and possibly long-term benefits to these patients.
The adoption of a minimally invasive approach for treatment of Junctional Esophago-Gastric adenocarcinoma has increased with the publication of several comparative trials showing equivalence in clinical outcomes with open surgery. However, in many countries, less than 50% of these surgical resections are undertaken by a completely minimally invasive or hybrid operation. The key surgical principles of both the open & minimally invasive approach for Junctional EG adenocarcinoma remain the same - achieving R0 resection margins, appropriate lymphadenectomy and restoration of upper gastrointestinal continuity with a suitable conduit. However, with continued improvements in multi-modal treatment options and survival, there is also a greater need to consider the associated morbidity and longer-term consequences of our interventions on survivorship.
This Research Topic aims to provide the reader with valuable and up to date information regarding the emerging and novel approaches (including Thoracoscopic, Laparoscopic and Robotic) for junctional EG adenocarcinoma. These techniques are predominantly undertaken by expert surgeons in high-volume tertiary centers and there is much interest in the short-term and long-term clinical outcomes as well as the technical subtleties associated with these minimally invasive surgical treatments.
We welcome Original Research, Leading-edge Reviews and Clinical Trials related but not limited to the aspects below:
- Surgical decision-making algorithms for a totally minimally invasive/robotic approach to junctional EG adenocarcinoma
- Perioperative Outcomes for totally minimally invasive and robotic esophagectomy/gastrectomy
- Operative technical Notes/Expert Tips & Tricks for all minimally invasive approaches (including intraoperative methods of assessment for borderline resectable tumours)
- Long-term survival and quality of life outcomes in patients, who have undergone minimally invasive surgical treatment for junctional EG adenocarcinoma
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Esophago-gastric (EG) cancer represents one of the cancers with the fastest rising incidence globally with 5-year overall survival of 15.1%. The variability of early signs in EG cancer result in only one-third of patients being suitable for potentially curative treatment at diagnosis. Chemotherapy +/- radiotherapy may have a role in this pathway however radical surgical resection remains critical to achieving long-term disease-free survival for our patients. Surgical techniques for junctional Esophago-Gastric adenocarcinoma vary with particular controversy and much scientific discussion regarding the optimal approach for Siewert Type II Esophago-Gastric cancers. The advent of minimally invasive techniques including thoracoscopic, laparoscopic and robotic have enhanced the EG resectional options and also bring significant potential short-term and possibly long-term benefits to these patients.
The adoption of a minimally invasive approach for treatment of Junctional Esophago-Gastric adenocarcinoma has increased with the publication of several comparative trials showing equivalence in clinical outcomes with open surgery. However, in many countries, less than 50% of these surgical resections are undertaken by a completely minimally invasive or hybrid operation. The key surgical principles of both the open & minimally invasive approach for Junctional EG adenocarcinoma remain the same - achieving R0 resection margins, appropriate lymphadenectomy and restoration of upper gastrointestinal continuity with a suitable conduit. However, with continued improvements in multi-modal treatment options and survival, there is also a greater need to consider the associated morbidity and longer-term consequences of our interventions on survivorship.
This Research Topic aims to provide the reader with valuable and up to date information regarding the emerging and novel approaches (including Thoracoscopic, Laparoscopic and Robotic) for junctional EG adenocarcinoma. These techniques are predominantly undertaken by expert surgeons in high-volume tertiary centers and there is much interest in the short-term and long-term clinical outcomes as well as the technical subtleties associated with these minimally invasive surgical treatments.
We welcome Original Research, Leading-edge Reviews and Clinical Trials related but not limited to the aspects below:
- Surgical decision-making algorithms for a totally minimally invasive/robotic approach to junctional EG adenocarcinoma
- Perioperative Outcomes for totally minimally invasive and robotic esophagectomy/gastrectomy
- Operative technical Notes/Expert Tips & Tricks for all minimally invasive approaches (including intraoperative methods of assessment for borderline resectable tumours)
- Long-term survival and quality of life outcomes in patients, who have undergone minimally invasive surgical treatment for junctional EG adenocarcinoma
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
